AOD-9604: Reference Overview and Reconstitution Notes

AOD-9604 is a man-made piece of the human growth hormone molecule. Researchers study it for its possible role in metabolism and weight regulation. It is not approved as a drug by any major government health agency.

AOD-9604

What it is

AOD-9604 is a man-made peptide (a short chain of amino acids, which are the building blocks of proteins). It matches a specific short section of human growth hormone, covering positions 176 to 191 at one end of that hormone. It also has a small change at the other end of this fragment. Scientists built this piece on its own rather than copying the whole hormone. That places it in the growth-hormone fragment family (small pieces taken from a larger hormone molecule).

Research context and categorization

Development and Focus Areas

AOD-9604 is mainly grouped under research on metabolism (how the body processes energy and nutrients) and weight regulation. It is also discussed in the context of healing and tissue repair. Scientists first developed it in the late 1990s as a possible drug candidate to fight obesity. Much of the early research focused on lipid metabolism and fat regulation (how the body breaks down and handles fat molecules).

Separately, AOD-9604 has been studied in animal and cell-culture (lab-grown cell) models for effects on cartilage and bone. This includes studies using collagenase-induced osteoarthritis models (a lab method where a chemical is used to break down cartilage in a joint, creating conditions similar to those seen in arthritis) where it has been examined alongside hyaluronic acid.

Mechanism of Action Differences

One point often highlighted in published research is that AOD-9604 has been reported not to bind the growth hormone receptor (the specific docking site on cells that the full growth hormone normally attaches to). Studies also found that it did not raise IGF-1 (insulin-like growth factor 1, a signaling protein closely tied to growth hormone activity). Because of this, researchers discuss it separately from full growth-hormone activity.

All of these uses are investigational. None are confirmed or approved outcomes. Much of the supporting work is preclinical or early-stage (meaning it was done in lab settings or animal models, not in large established human trials) rather than proven human results.

Key point: Studies report that AOD-9604 does not bind the growth hormone receptor or raise IGF-1, distinguishing its mechanism from full growth-hormone activity.

Status

• Regulatory status: Research-only, not FDA-approved as a drug for any medical use. It went through a clinical development program (a series of formal human studies required before a substance can become an approved drug) that did not result in approval. Its compounding status in the United States (whether pharmacies could prepare special formulations of it) has shifted over time. A GRAS (Generally Recognized As Safe) determination has been cited for oral food-ingredient use only. This is different from drug approval and does not cover injectable preparations.
• Sport status: Prohibited under the WADA Prohibited List (the World Anti-Doping Agency's list of substances banned in competitive sport). WADA has stated that AOD-9604 falls under the S0 category (non-approved substances, meaning those with no current government approval for human therapeutic use). As a growth-hormone fragment, it is also discussed in relation to the S2 class (peptide hormones, growth factors, and related substances). It was a central subject in the Essendon anti-doping case in Australia.

Reconstitution notes (general)

For lyophilized (freeze-dried) peptides supplied as a powder, concentration is the milligrams of powder in the vial divided by the millilitres of bacteriostatic water added. Think of it like mixing a powdered drink: the more water you add, the weaker the final mix.

• For example, 5 mg reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL.

To work out any combination of vial size and diluent volume, use the calculator at peptide calculator.

Dilution and handling notes (compound-specific)

AOD-9604 ships as a lyophilized powder and is reconstituted (dissolved back into liquid form) before laboratory use. A commonly referenced range is about 2 mL to 3 mL of bacteriostatic water per 5 mg vial. The exact volume is chosen to reach a target concentration. A correctly reconstituted solution should be clear and colorless.

Solubility Challenges

One practical quirk with this peptide is that it does not always dissolve into a perfectly clear liquid. It has relatively low intrinsic water solubility (it does not mix easily into water on its own). The result can be a cloudy or hazy solution, or even partial clumping, especially at higher concentrations. Think of it like trying to dissolve too much sugar in a cold glass of water: some of it simply will not mix in cleanly.

Handling Best Practices

Two handling steps help reduce that tendency:

1. Method of addition: Add the liquid slowly down the inner wall of the vial rather than directly onto the powder. Then let the vial rest and swirl it gently. This works better than adding the liquid quickly.
2. Agitation: Swirling is preferred over shaking. Vigorous shaking foams the solution and is thought to stress the peptide.

Troubleshooting Persistent Haze

If haze remains, some protocols let the vial sit for several minutes and then swirl again.

A small amount of a mild acidifying diluent, such as dilute acetic acid (a weak acid, similar in type to vinegar but used in a highly diluted lab form), added slowly alongside the bacteriostatic water, is sometimes described as an aid for difficult dissolution. Plain bacteriostatic water is still the standard starting point.

Handling and storage

Proper storage and preparation help keep the peptide stable. Key storage guidelines include:

• Refrigerate the reconstituted vial at 2 to 8 degrees Celsius and keep it away from light.
• Wipe the stopper with an alcohol swab before drawing from the vial.
• Label the vial with the date it was mixed.

A refrigerated window of roughly four weeks is commonly cited for the reconstituted solution.

Discard the material if it turns cloudy in a new way (different from any haziness present right after mixing), changes color, or shows visible particles or floaters that were not there at reconstitution.

Related reading

• BPC-157
• Bronchogen
• Cardiogen
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

Does AOD-9604 bind the growth hormone receptor or raise IGF-1?

Published studies report AOD-9604 does not bind the growth hormone receptor and does not elevate IGF-1, distinguishing its investigated mechanism from full growth-hormone activity in preclinical models.

What is the regulatory and anti-doping status of AOD-9604?

AOD-9604 is not approved as a drug by any major agency. WADA lists it under S0 (non-approved substances). A GRAS determination covers oral food-ingredient use only and does not extend to injectable preparations.

What research models have been used to study AOD-9604?

Studies have employed animal models, cell-culture systems, and collagenase-induced osteoarthritis models. A formal human clinical program was conducted but did not result in drug approval; all findings remain investigational.

What the research community gets wrong about AOD-9604

• Treating it like growth hormone. Because AOD-9604 is copied from a piece of growth hormone, it is easy to file it next to growth hormone in your notes. Published work reports that it does not bind the growth hormone receptor and does not raise IGF-1, so it behaves differently in study models and should be logged on its own terms.
• Expecting a perfectly clear vial every time. This peptide has low water solubility, so a cloudy or hazy solution right after mixing is common, especially at higher concentrations. Some haze at reconstitution is not automatic proof the material has gone bad.
• Mixing up GRAS with drug approval. A GRAS (Generally Recognized As Safe) determination has been cited only for oral food-ingredient use. That is not the same as FDA drug approval, and it says nothing about injectable lab preparations.
• Reading the weight studies as settled. The largest human obesity trial did not meet its main goal, and drug development was stopped in 2007. Much of the supporting work is preclinical (animal and cell-culture models), not confirmed human results.
• Shaking hard to force it into solution. Vigorous shaking foams the liquid and is thought to stress the peptide. Adding water slowly down the vial wall and then swirling gently is the usual approach.

From our bench: If you reconstitute an AOD-9604 vial and see haze, we want your real observation. Add bacteriostatic water slowly down the wall, swirl, and note whether the cloudiness clears on its own after resting and, if so, roughly how long it took at your bench temperature. Tell us the vial size, the diluent volume you used, and whether the solution ever went fully clear or stayed hazy. We will add real reader logs (no invented numbers) to this page.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. AOD-9604, PubChem Compound Summary (CID 71300630), National Library of Medicine
5. Wilding J. AOD-9604 (Metabolic). Curr Opin Investig Drugs. 2004;5(4):436-40 (PMID 15134286)
6. Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-432